Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2

Conditions

Leiomyoma 4Uterine Hemorrhage 2

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × ulipristal acetate × Clear all
NCT00290251 2024-07-15

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
72 enrolled 7 charts

Leiomyoma

NCT01629563 2019-09-04

PEARLIV

PregLem SA

Phase 3 Completed
451 enrolled 14 charts

Leiomyoma

NCT02147158 2019-06-04

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

Allergan

Phase 3 Completed
432 enrolled 16 charts
Gynecologic

Leiomyoma, Uterine Hemorrhage

NCT02147197 2019-04-30

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Allergan

Phase 3 Completed
157 enrolled 11 charts
Gynecologic

Leiomyoma, Uterine Hemorrhage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡